Current knowledge of thrombocytopenia in sepsis and COVID-19

Thrombocytopenia, characterized by a decrease in platelet count, is commonly observed in sepsis and COVID-19. In sepsis, thrombocytopenia can result from various mechanisms, including impaired platelet production in the bone marrow, accelerated platelet destruction due to increased inflammation, seq...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-09, Vol.14, p.1213510
Main Authors: Cheng, Junjie, Zeng, Hanhai, Chen, Huaijun, Fan, Linfeng, Xu, Chaoran, Huang, Huaping, Tang, Tianchi, Li, Min
Format: Article
Language:English
Subjects:
Anemia
Blood Platelets
COVID-19
Humans
Immunology
platelet
Platelet Count
sepsis
Sepsis - complications
Sepsis - therapy
thrombocytopenia
Thrombocytopenia - etiology
Thrombocytopenia - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombocytopenia, characterized by a decrease in platelet count, is commonly observed in sepsis and COVID-19. In sepsis, thrombocytopenia can result from various mechanisms, including impaired platelet production in the bone marrow, accelerated platelet destruction due to increased inflammation, sequestration of platelets in the spleen, immune-mediated platelet destruction, or dysregulated host responses. Similarly, thrombocytopenia has been reported in COVID-19 patients, but the immune-related mechanisms underlying this association remain unclear. Notably, interventions targeting thrombocytopenia have shown potential for improving outcomes in both sepsis and COVID-19 patients. Understanding these mechanisms is crucial for developing effective treatments.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1213510